Gonadotropin-Releasing Hormone Agonist Synarel
Defines medical necessity criteria, prior authorization recommendations, approval durations, covered indications (central precocious puberty, endometriosis, and supportive use for gender-dysphoric persons), exclusions (peripheral precocious puberty and other uses), and billing/code guidance for Synarel under Cigna benefit plans.
Updated pubertal basal LH threshold from 0.3 to 0.2 mIU/mL.
Added exception allowing waiver of trial of first-line therapies for endometriosis if patient previously used a GnRH agonist or antagonist for endometriosis.
Policy title updated from 'Nafarelin Acetate' to 'Gonadotropin Releasing Hormone Agonist - Synarel'.
Added new criterion under 'Other Uses with Supportive Evidence' to include gender‑dysphoric/gender‑incongruent persons undergoing gender reassignment.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.